Evaluation of the safety and efficacy of m-beam and m-beac regimen for autologous hematopoietic stem-cell transplantation pretreatment due to the shortage supply of melphalan (the second report)

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: MIYAGAWA, Keiko (Kameda Medical Center, Kamogawa, Chiba, Japan)
  • Co-author(s): Keiko Miyagawa: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
    Yusuke Nakagawa: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
    Tatsuya Isezaki: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
    Koji Masuda: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
    Osamu Yasumuro: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
    Kosei Matsue: Department of Hematology, Kameda Medical Center, Chiba, Japan
    Ryokan Funakoshi: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
  • Abstract:

    Background

    Melphalan IV (Mel) distribution has been suspended globally due to manufacturing process difficulties occurring in November 2015. We have been using the combination of Ranimustine/Etoposide/Cytarabine/Cyclophosphamide (M-BEAC) as pretreatment for autologous stem-cell transplantation (ASCT) instead of..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login